These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1605292)

  • 41. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ; Ho KK; Lazarus L
    J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
    Rohr UD; Ehrly AM; Kuhl H
    Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Estrogen therapy in menopause. Clinical study in evolution (KEEPS) to explain the risk-benefit dispute to administration].
    Zárate A; Hernández-Valencia M
    Ginecol Obstet Mex; 2010 Mar; 78(3):191-4. PubMed ID: 20939224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and validation of an objective method of determining skin erythema to transdermal oestradiol patches.
    Ross D; Whitehead M; Pike B
    Br J Obstet Gynaecol; 1999 Mar; 106(3):279-83. PubMed ID: 10426650
    [No Abstract]   [Full Text] [Related]  

  • 48. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
    Sajtos B; Herold J; Winkler UH; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intranasal estradiol: new formulation. Intranasal oestrogen delivery system: just a gimmick.
    Prescrire Int; 2002 Dec; 11(62):163-5. PubMed ID: 12469692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of a transdermal continuous combined and an interrupted progestogen HRT.
    Cameron ST; Glasier AF; Gebbie A; Dewart H; Baird DT
    Maturitas; 2006 Jan; 53(1):19-26. PubMed ID: 16325020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized comparison of nonoral estradiol delivery in postmenopausal women.
    Stanczyk FZ; Shoupe D; Nunez V; Macias-Gonzales P; Vijod MA; Lobo RA
    Am J Obstet Gynecol; 1988 Dec; 159(6):1540-6. PubMed ID: 3144919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Kinetics of a new patch for transdermal administration of 17 beta-estradiol].
    Rohr UD; Nauert C; Ehrly AM
    Zentralbl Gynakol; 1995; 117(10):531-9. PubMed ID: 7491836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The effect of transdermal hormone replacement therapy on vasomotor symptoms in perimenopausal women].
    Rozmus-Warcholińska W; Skrzypulec V; Drosdzol A; Kowalczyk R; Nowosielski K; Piela B; Walaszek A
    Wiad Lek; 2004; 57 Suppl 1():254-8. PubMed ID: 15884251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Systen--transdermal estradiol for substitution following surgical menopause].
    Rachev E; Karag'ozov I
    Akush Ginekol (Sofiia); 1995; 34(3):74-6. PubMed ID: 8743861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hormone substitution therapy. Side-effects and compliance of various therapeutic regimens].
    Perrone G; Barillaro F; Bazzoffi R; Capri O; Critelli C; Galoppi P; Grande S; Santoro G
    Minerva Ginecol; 1999 Mar; 51(3):53-8. PubMed ID: 10352534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
    Rachev E
    Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effectiveness and tolerance of pulsed estrogen therapy in the treatment of menopausal symptoms. Results of a Polish multicenter study].
    Szamatowicz M
    Ginekol Pol; 2005 Mar; 76(3):245-51. PubMed ID: 16018146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism].
    Giuliani A; Concin H; Wieser F; Boritsch J; Wilfert H; Gruber D; Urdl W
    Wien Klin Wochenschr; 2000 Jul; 112(14):629-33. PubMed ID: 11008325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of acute ethanol ingestion on prolactin in menopausal women using estradiol replacement.
    Ginsburg ES; Walsh BW; Shea BF; Gao X; Gleason RE; Feltmate C; Barbieri RL
    Gynecol Obstet Invest; 1995; 39(1):47-9. PubMed ID: 7890253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transdermal administration of oestrogen/progestagen hormone replacement therapy.
    Whitehead MI; Fraser D; Schenkel L; Crook D; Stevenson JC
    Lancet; 1990 Feb; 335(8685):310-2. PubMed ID: 1967769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.